The CASTRO study will show whether CRP apheresis can be safely performed in patients with ischemic stroke and also provide preliminary results whether reducing the concentration of serum CRP levels facilitates reduction of tissue damage of the brain, consequently improving clinical outcome measures compared to the control group. The gene discussed is CRP; the disease is ischemic stroke.